高级混合闭环对使用多次每日注射的高危 1 型糖尿病青少年的影响。
Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections.
机构信息
1Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand.
2Department of Paediatrics, University of Otago, Christchurch, New Zealand.
出版信息
Diabetes Care. 2023 Mar 1;46(3):628-632. doi: 10.2337/dc22-1971.
OBJECTIVE
To evaluate glycemic outcomes in youth (aged 13-25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.
RESEARCH DESIGN AND METHODS
This prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.
RESULTS
HbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70-180 mg/dL (3.9-10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.
CONCLUSIONS
AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.
目的
评估在接受多次每日注射（MDI）治疗后转为先进混合闭环（AHCL）治疗的 13-25 岁、血糖控制高风险（HbA1c≥8.5%[69mmol/mol]）的 1 型糖尿病青年患者的血糖控制结果。
研究设计与方法
这是一项前瞻性、3 个月、单臂、双中心研究，共纳入 20 名参与者，所有人均完成了研究。
结果
HbA1c 从基线时的 10.5±2.1%（91.2±22.8mmol/mol）降至 7.6±1.1%（59.7±11.9mmol/mol），目标范围内时间（70-180mg/dL[3.9-10.0mmol/L]）从基线时的 27.6±13.2%增加到 3 个月时的 66.5±9.8%。有两起因输注套件故障导致的糖尿病酮症酸中毒事件。
结论
AHCL 有可能改善之前接受 MDI 治疗的 1 型糖尿病青年患者的血糖控制不佳的情况。
Zotero 插件